Differentiation therapy as an effective strategy for the treatment of chronic myelogenous leukemia.
Moosavi
Mohammad Amin
MA
Yazdanparast
Razieh
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002454:Cell Differentiation / Q000187:drug effects* / Q000502:physiology; D016922:Cellular Senescence / Q000187:drug effects / Q000502:physiology; D006160:Guanosine Triphosphate / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008954:Models, Biological; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000502:physiology; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D006160:Guanosine Triphosphate; D000068877:Imatinib Mesylate